Format

Send to

Choose Destination
J Neurooncol. 2017 Jan;131(2):201-211. doi: 10.1007/s11060-016-2303-x. Epub 2016 Nov 11.

Withaferin A and its potential role in glioblastoma (GBM).

Author information

1
Health Sciences Center, Texas Tech University, El Paso, TX, USA.
2
Department of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA.
3
Department of Radiology, Molecular Imaging Program at Stanford and Canary Center at Stanford for Early Cancer Detection, Stanford University, Palo Alto, CA, USA. sgambhir@stanford.edu.

Abstract

Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid's potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A's anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.

KEYWORDS:

Anticancer; Ashwagandha; Glioblastoma; Immunomodulation; Oncogenic pathways; Pharmacodynamics; Pharmacokinetics; Pharmacological; Withaferin A; Withania somnifera; Withanolides

PMID:
27837436
DOI:
10.1007/s11060-016-2303-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center